-+ 0.00%
-+ 0.00%
-+ 0.00%

D. Boral Capital Maintains Buy on UroGen Pharma, Maintains $25 Price Target

Benzinga·04/28/2025 11:33:28
Listen to the news
D. Boral Capital analyst Jason Kolbert maintains UroGen Pharma (NASDAQ:URGN) with a Buy and maintains $25 price target.